Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

TriSalus Life Sciences FY2025 Revenue expected to be more than $44.147M vs $44.837M Est. Revenue for 2025 FY is expected to up by more than 50% YoY from $29.431M.

Author: Benzinga Newsdesk | August 12, 2025 04:03pm

TriSalus Life Sciences (NASDAQ:TLSI) FY2025 Revenue expected to be more than $44.147M vs $44.837M Est. Revenue for 2025 FY is expected to up by more than 50% YoY from $29.431M

Posted In: TLSI


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist